Nifty
Sensex
:
:
22399.15
73847.15
-136.70 (-0.61%)
-379.93 (-0.51%)

Pharmaceuticals & Drugs - API

Rating :
N/A

BSE: 524164 | NSE: IOLCP

383.60
06-Feb-2025
  • Open
  • High
  • Low
  • Previous Close
  •  375.50
  •  391.40
  •  375.50
  •  375.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  327906
  •  1260.29
  •  391.40
  •  57.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,740.91
  • 17.90
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,718.45
  • 1.69%
  • 1.04

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.62%
  • 10.95%
  • 31.23%
  • FII
  • DII
  • Others
  • 1.49%
  • 0.02%
  • 3.69%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.68
  • 2.40
  • -0.79

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 35.29
  • -16.60
  • -2.24

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -17.82
  • -7.10

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.55
  • 16.55
  • 16.55

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 1.48
  • 1.48
  • 1.48

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 8.80
  • 8.80
  • 8.80

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Net Sales
523.30
520.39
0.56%
525.75
545.30
-3.59%
502.38
563.18
-10.80%
503.92
587.21
-14.18%
Expenses
476.43
476.04
0.08%
484.18
481.10
0.64%
451.27
490.66
-8.03%
454.40
491.91
-7.63%
EBITDA
46.87
44.35
5.68%
41.57
64.20
-35.25%
51.11
72.52
-29.52%
49.52
95.30
-48.04%
EBIDTM
8.96%
8.52%
7.91%
11.77%
10.17%
12.88%
9.83%
16.23%
Other Income
4.07
8.38
-51.43%
6.43
7.11
-9.56%
7.38
7.06
4.53%
7.52
8.73
-13.86%
Interest
4.46
4.30
3.72%
4.12
4.44
-7.21%
2.15
3.95
-45.57%
3.41
4.88
-30.12%
Depreciation
18.68
16.34
14.32%
17.94
15.69
14.34%
16.82
14.45
16.40%
16.43
12.11
35.67%
PBT
27.80
32.09
-13.37%
25.94
51.18
-49.32%
39.52
61.18
-35.40%
37.20
87.04
-57.26%
Tax
7.27
9.01
-19.31%
6.79
13.31
-48.99%
9.55
15.32
-37.66%
9.58
22.26
-56.96%
PAT
20.53
23.08
-11.05%
19.15
37.87
-49.43%
29.97
45.86
-34.65%
27.62
64.78
-57.36%
PATM
3.92%
4.44%
3.64%
6.94%
5.97%
8.14%
5.48%
11.03%
EPS
0.70
0.79
-11.39%
0.65
1.29
-49.61%
1.02
1.56
-34.62%
0.94
2.21
-57.47%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Net Sales
2,055.35
2,132.79
2,217.11
2,184.02
Net Sales Growth
-7.25%
-3.80%
1.52%
 
Cost Of Goods Sold
1,368.58
1,396.95
1,547.09
1,570.51
Gross Profit
686.77
735.84
670.02
613.51
GP Margin
33.41%
34.50%
30.22%
28.09%
Total Expenditure
1,866.28
1,902.20
1,991.44
1,925.73
Power & Fuel Cost
-
149.05
131.98
78.18
% Of Sales
-
6.99%
5.95%
3.58%
Employee Cost
-
201.02
168.21
141.30
% Of Sales
-
9.43%
7.59%
6.47%
Manufacturing Exp.
-
47.67
43.07
36.86
% Of Sales
-
2.24%
1.94%
1.69%
General & Admin Exp.
-
9.01
6.54
5.12
% Of Sales
-
0.42%
0.29%
0.23%
Selling & Distn. Exp.
-
51.25
61.85
66.84
% Of Sales
-
2.40%
2.79%
3.06%
Miscellaneous Exp.
-
47.25
32.70
26.92
% Of Sales
-
2.22%
1.47%
1.23%
EBITDA
189.07
230.59
225.67
258.29
EBITDA Margin
9.20%
10.81%
10.18%
11.83%
Other Income
25.40
30.07
25.61
32.04
Interest
14.14
16.10
16.47
8.29
Depreciation
69.87
62.91
46.16
43.26
PBT
130.46
181.65
188.65
238.78
Tax
33.19
47.22
49.51
57.18
Tax Rate
25.44%
26.00%
26.24%
25.43%
PAT
97.27
134.43
139.14
167.67
PAT before Minority Interest
97.27
134.43
139.14
167.67
Minority Interest
0.00
0.00
0.00
0.00
PAT Margin
4.73%
6.30%
6.28%
7.68%
PAT Growth
-43.31%
-3.39%
-17.02%
 
EPS
16.57
22.90
23.70
28.56

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Shareholder's Funds
1,611.51
1,507.72
1,392.28
Share Capital
58.71
58.71
58.71
Total Reserves
1,552.80
1,449.01
1,333.57
Non-Current Liabilities
72.89
58.15
56.62
Secured Loans
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
Long Term Provisions
6.71
1.65
3.01
Current Liabilities
597.10
502.52
575.29
Trade Payables
469.18
314.22
409.29
Other Current Liabilities
54.67
54.28
54.02
Short Term Borrowings
32.76
79.63
42.75
Short Term Provisions
40.49
54.39
69.23
Total Liabilities
2,281.50
2,068.39
2,024.19
Net Block
933.13
751.81
560.64
Gross Block
1,236.94
995.24
761.99
Accumulated Depreciation
303.81
243.43
201.35
Non Current Assets
1,124.63
1,101.74
881.48
Capital Work in Progress
100.87
89.64
105.20
Non Current Investment
17.41
17.41
0.00
Long Term Loans & Adv.
23.62
9.52
10.77
Other Non Current Assets
49.60
233.36
204.87
Current Assets
1,156.87
966.65
1,142.71
Current Investments
2.88
2.56
2.37
Inventories
424.84
325.52
409.89
Sundry Debtors
471.23
505.28
469.80
Cash & Bank
142.89
21.83
139.99
Other Current Assets
115.03
29.86
30.99
Short Term Loans & Adv.
90.12
81.60
89.67
Net Current Assets
559.77
464.13
567.42
Total Assets
2,281.50
2,068.39
2,024.19

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Cash From Operating Activity
290.08
122.27
93.05
PBT
181.65
188.65
224.85
Adjustment
60.12
44.41
33.12
Changes in Working Capital
90.33
-63.69
-102.34
Cash after chg. in Working capital
332.10
169.37
155.63
Interest Paid
0.00
0.00
0.00
Tax Paid
-42.02
-47.10
-62.58
Other Direct Exp. Paid
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
Cash From Investing Activity
-191.28
-120.00
-120.52
Net Fixed Assets
-252.93
-217.16
Net Investments
-0.32
-17.80
Others
61.97
114.96
Cash from Financing Activity
-92.50
-4.11
-1.64
Net Cash Inflow / Outflow
6.30
-1.84
-29.11
Opening Cash & Equivalents
1.39
3.23
32.34
Closing Cash & Equivalent
7.69
1.39
3.23

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Book Value (Rs.)
54.90
256.81
237.15
ROA
6.18%
6.80%
8.28%
ROE
8.62%
9.60%
12.04%
ROCE
12.24%
13.57%
16.25%
Fixed Asset Turnover
1.91
2.52
2.87
Receivable days
83.56
80.26
78.51
Inventory Days
64.21
60.53
68.50
Payable days
102.34
85.35
95.12
Cash Conversion Cycle
45.42
55.45
51.89
Total Debt/Equity
0.02
0.05
0.03
Interest Cover
12.28
12.45
28.12

News Update:


  • IOL Chemicals commences new Unit 11 for Paracetamol production in Punjab
    25th Mar 2025, 11:09 AM

    The company has enhanced the installed capacity of Unit 5 for manufacturing Clopidogrel Bisulphate from 180 MTPA to 240 MT

    Read More
  • IOL Chemicals and Pharmaceuticals gets Certificate of Suitability from EDQM
    6th Mar 2025, 14:19 PM

    This certification will enable the company to export Quetiapine Fumarate to European and other countries

    Read More
  • IOL Chemicals and Pharmaceuticals reports 11% fall in Q3 consolidated net profit
    13th Feb 2025, 15:28 PM

    Total consolidated income of the company decreased marginally at Rs 527.37 crore for Q3FY25

    Read More
  • IOL Chem & Pharma - Quarterly Results
    12th Feb 2025, 18:05 PM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.